A subset of equine sarcoids harbours BPV-1 DNA in a complex with L1 major capsid protein  by Brandt, S. et al.
Available online at www.sciencedirect.com
8) 433–441
www.elsevier.com/locate/yviroVirology 375 (200A subset of equine sarcoids harbours BPV-1 DNA in a
complex with L1 major capsid protein
S. Brandt a,⁎, R. Haralambus b, S. Shafti-Keramat c, R. Steinborn d,e, C. Stanek f, R. Kirnbauer c
a Equine Biotechnology Unit (EBU), Equine Centre, Veterinary University Vienna, Veterinaerplatz 1, 1210 Vienna, Austria
b Equine Clinic, Vetsuisse Faculty, University of Berne, Berne, Switzerland
c Laboratory of Viral Oncology (LVO), Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology,
Medical University Vienna, Vienna, Austria
d Institute of Animal Breeding and Genetics, Veterinary University Vienna, Vienna, Austria
e VetOMICS Core Facility, Veterinary University Vienna, Vienna, Austria
f Clinic for Orthopaedics in Ungulates, Equine Centre, Veterinary University Vienna, Vienna, Austria
Received 6 November 2007; returned to author for revision 30 November 2007; accepted 14 February 2008
Available online 18 April 2008Abstract
Bovine papillomavirus type 1 or 2 (BPV-1, BPV-2) are accepted causal factors in equine sarcoid pathogenesis. Whereas viral genomes are
consistently found and expressed within lesions, intact virions have never been detected, thus permissiveness of sarcoids for BPV-1 replication
remains unclear. To reassess this issue, an immunocapture PCR (IC/PCR) was established using L1-specific antibodies to capture L1-DNA
complexes followed by amplification of the viral genome. Following validation of the assay, 13 sarcoid-bearing horses were evaluated by IC/PCR.
Samples were derived from 21 tumours, 4 perilesional/intact skin biopsies, and 1 serum. Tissue extracts from sarcoid-free equines served as
controls. IC/PCR scored positive in 14 /24 (58.3%) specimens obtained from sarcoid-patients, but negative for controls. Quantitative IC/PCR
demonstrated b125 immunoprecipitable viral genomes/50 µl extract for the majority of specimens. Moreover, full-length BPV-1 genomes were
detected in a complex with L1 proteins. These complexes may correspond to virion precursors or intact virions.
© 2008 Elsevier Inc. All rights reserved.Keywords: Bovine papillomavirus; Equine sarcoid; Virions; Immunocapture PCRIntroduction
Bovine papillomaviruses (BPV) are of considerable veter-
inary and agricultural importance. In their natural bovine host,
they induce hyperproliferative lesions of cutaneous or mucosal
epithelia that usually regress spontaneously without treatment.
In some cases however, lesions undergo malignant transforma-
tion to squamous cell carcinomas (Campo, 2002, 2006).
Like other papillomaviruses, BPV virions are non-enveloped
icosahedral structures of 55–60 nm in diameter harbouring
circular, double-stranded DNA of 7.3 (BPV-3, -4, -6) or 8 kb
(BPV-1, -2, -5). The genome consists of a long control region
containing the cis-regulatory elements required for replication⁎ Corresponding author. Fax: +43 25077 5390.
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doi:10.1016/j.virol.2008.02.014and transcription of viral DNA, an early gene region coding for
non-structural proteins including viral oncoproteins E5, E6, and
E7, and a late gene region coding for the major L1 and the minor
L2 capsid proteins. Infectious BPV virions have been isolated
from bovine papillomas demonstrating productive infection in
the habitual bovine host (Campo, 2006).
In addition to causing disease in cows, BPV-1 and BPV-2 are
aetiologically involved in the development and maintenance
of benign, yet locally aggressive cutaneous lesions termed
sarcoids, which frequently affect equids all over the world
(Sullins et al., 1986). This etiologic association represents the
only example of a natural papillomavirus cross-species infection
documented so far (Amtmann et al., 1980; Angelos et al., 1991;
Bloch et al., 1994; Carr et al., 2001a,b; Chambers et al., 2003a;
Lancaster et al., 1979; Lory et al., 1993; Nasir and Reid, 1999;
Otten et al., 1993; Reid et al., 1994; Trenfield et al., 1985).
434 S. Brandt et al. / Virology 375 (2008) 433–441Sarcoids occur as single or multiple skin lesions and often
develop at sites of previous injury and scarring (Ragland et al.,
1970; Torrontegui and Reid, 1994). In contrast to bovine
papillomas, sarcoids usually persist, are refractory to therapy and
tend to recrudesce following excision (Chambers et al., 2003a).
According to their presentation tumours are classified as occult,
verrucous, nodular, fibroblastic or mixed type lesion (Pascoe and
Knottenbelt, 1999). A causal role for BPV was first suspected
when experimental inoculation of equine skin with sarcoid
extract or purified BPV led to the development of transient
sarcoid-like lesions (Olson and Cook, 1951; Ragland and
Spencer, 1969; Voss, 1969). Subsequently, Southern blot
revealed BPV DNA in sarcoids from horses and donkeys
(Amtmann et al., 1980; Lancaster et al., 1979). Using more
sensitive PCR technology, BPV-1 or BPV-2 DNA has been
detected in up to 100% of lesions (Bloch et al., 1994; Carr et al.,Table 1
Investigated sample specimens: specifications, PCR, IC/PCR and IC/qPCR results
Horse Sample No. Sample type Collection site E5 PC
Patient group
A A1 Verrucous sarcoid Penis 1
A2 Verrucous sarcoid Penis 1
B B3 Fibroblastic sarcoid Ear 1
B4 Fibroblastic sarcoid Ear 1
C C5 PBMCs Whole blood 1
C6 Intact skin Neck 1
C7 Fibroblastic sarcoid Prepuce 1
D D8 Mixed sarcoid Prepuce 1
D9 Mixed sarcoid Prepuce 1
D10 Mixed sarcoid Prepuce 1
D11 Serum Whole blood n.d.
E E12 Verrucous sarcoid Crown 1
F F13 Fibroblastic sarcoid Stifle 1
F14 Fibroblastic sarcoid Anterior chest 1
G G15 Fibroblastic sarcoid Left ear 1
G16 Nodular sarcoid Right ear 1
G17 Intact skin Neck 1
H H18 Mixed sarcoid Fetlock 1
J J19 Mixed sarcoid Hind leg 1
J20 Mixed sarcoid Hind leg 1
J21 Mixed sarcoid Hind leg 1
J22 Perilesional skin Hind leg 1
K K23 Fibroblastic sarcoid Nostrils 1
K24 Intact skin Neck 1
L L25 Verrucous sarcoid Chest 1
M M26 Fibroblastic sarcoid Elbow 1
N N27 Verrucous sarcoid Neck 1
N28 Nodular sarcoid Prepuce 1
N29 Perilesional skin Prepuce 1
O O30 Dermatitis Hind leg 1
O31 Intact skin Neck 1
Control group (-c; sarcoid-free individuals)
P P32 Intact skin Scrotum 0
Q Q33 Intact skin Umbilicus 0
R R34 Intact skin Scrotum 0
S S35 Mastocytoma Fore leg 0
T T36 Melanoma Peritoneum 0
T37 Cartilage Peritoneum 0
1: positive; 0: negative; n.d.: not done; SD: standard deviation of duplicates.
Italic: only DNA isolation performed, no extract available due to small sample size2001a,b; Martens et al., 2001a,b; Otten et al., 1993) and also in
intact skin of sarcoid-bearing individuals (Carr et al., 2001b).
Conversely, BPV DNA cannot be detected in horses without
sarcoids or in non-sarcoid equine tumours (Carr et al., 2001a,b;
Otten et al., 1993; personal observation). However, BPV DNA
has been shown in skin swabs of some unaffected horses living
in close contact with sarcoid-bearing animals (Bogaert et al.,
2005). In addition, episomal BPV-1 genomes (Angelos et al.,
1991; Chambers et al., 2003b) and expression of viral early
genes have been demonstrated in dermatitis-affected equine skin
(Yuan et al., 2007a).
In sarcoids, BPV DNA resides as multiple episomal copies
within the nuclei of infected cells (Amtmann et al., 1980;
Campo, 2002; Yuan et al., 2007b). Viral early and late genes
have been demonstrated to be intralesionally transcribed
(Carr et al., 2001a; Nasir and Reid, 1999; Nixon et al., 2005)R L1 PCR IC/PCR Number of complexes/50 μl extract±SD
0 0
1 0
1 1 n.d.
1 n.d.
0 n.d.
1 n.d.
1 1 n.d.
1 1 b125
1 1 b125
1 1 b125
n.d. 0
1 0
1 1 118,500±10,610
1 1 b125
1 1 b125
1 1 b125
1 0
0 0
1 0
1 0
1 0
1 1 b125
n.d. 1 Not detectable
n.d. 1 b125
1 0
1 1 b125
1 1 b125
1 1 52,800±2970
1 1 254±30
0 0
n.d. 0
0 0 Not detectable
0 0 Not detectable
0 0 Not detectable
0 n.d.
0 n.d.
0 n.d.
.
Fig. 1. IC/PCR scores positive in case of an ulcerated fibroblastic sarcoid. Top: PCR from purified DNA revealed presence of L1 in case of a verrucous (A2) and two
fractions of a fibroblastic (B3, B4) sarcoid, whereas DNA of another verrucous sarcoid (A1) derived from patient A scored negative. DNA obtained from a
mastocytoma (S35), a melanoma (T37) and cartilage of the melanoma-bearing mare (T36) tested negative, as anticipated. Bottom: When using IC/PCR however,
extract of both verrucous sarcoids of same origin (A1, A2) scored negative, whereas extract from fibroblastic tumour B3 tested positive by this method, thus suggesting
the presence of capsid protein-complexed BPV-1 DNA in this lesion. M: GeneRuler™ 100 bp DNA Ladder Plus (Fermentas); p+: plasmid positive control (BPV1-
pML plasmid, PCR step only); v+: BPV-1 virion positive control.
435S. Brandt et al. / Virology 375 (2008) 433–441providing additional evidence of viral involvement in sarcoid
pathogenesis. Infectious virions have not been detected
in equine sarcoids so far (Amtmann et al., 1980; Lancaster,
1981), leading to the assumption that horses are non-
permissive hosts for BPV (Campo, 2002; Chambers et al.,
2003a).
However, previous failure to demonstrate BPV virions in
sarcoids may be due to very low particle concentrations.
Alternatively, virion formation may be restricted to particular
developmental stages of the tumour (Campo, 2002), or remain
incomplete in horses. To reassess this issue, a previously
established single tube immunocapture PCR (IC/PCR) protocol
(Brandt et al., 1993) was adapted for detection of L1 capsid
protein-associated BPV-1 DNA in samples from various equine
sarcoid types and skin of affected horses. Given that IC/PCR
combines the specificity of an immune-affinity capture step
with the sensitivity of PCR for selective amplification of
antigen-associated viral nucleic acids (Jansen et al., 1990), this
method is suitable for detection of extremely low amounts of
virions or premature assemblies against the background of
crude tissue extract.Fig. 2. IC/PCR specifically detects BPV-1 major capsid protein-associated viral DNA.
a fibroblastic sarcoid (C7 DNA) of one affected individual. a) PCR revealed L1-spec
(lane 1). b) Skin extract was prepared from a virus-free horse (S35) and spiked with C
DNA served as control. IC/PCR scored negative for all DNA-spiked extracts (lanes 2–
supernatant of the fibroblastic sarcoid (C7) as IC/PCR template. Amounts of L1-posit
M: GeneRuler™ 100 bp DNA Ladder Plus (Fermentas).Results
PCR reveals E5 in 100% and L1 in 84% of DNA samples from
equine patients
In the first step, samples were obtained from 13 sarcoid-
bearing horses and 1 individual affected by dermatitis (patient
group). As a control biopsies were obtained from 3 healthy
horses and 2 with BPV-unrelated tumours (control group) (see
Table 1 for details). Whole cellular DNA was isolated and
subjected to PCR amplification using BPV-1/-2 consensus
primers specific for E5 and L1. Hundred percent (30 /30) of
DNAs from the patient group tested positive for E5 by PCR,
including one peripheral blood mononuclear cell (PBMC)
sample (C5) (Table 1). In contrast, E5 was not detected in skin
of 3 healthy individuals, and 2 horses with a mastocytoma and a
melanoma, respectively. Sequencing of E5 amplimers obtained
from sarcoid A2 and B3 DNA revealed 100% identity to BPV-1
variant Swiss III E5 (Genbank accession number AY232259).
AnL1-specific 266 bp regionwas amplified from85% (23/27)
of DNA isolates from the patient group. One penile verrucousDNAwas isolated from PBMC (C5 DNA), intact distant skin (C6 DNA) or from
ific amplimers in skin and tumour DNA (lanes 3 and 4), but not in PBMC DNA
6 DNA or C7 DNA (5× the amount used in 1a). S35 spiked with L1-negative C5
4), whereas the reaction produced high yields of L1 amplicon when using extract
ive DNA used as template in (a) and for extract spiking in (b) are indicated in µg.
Fig. 3. Sensitive IC/PCR-mediated detection of capsid protein-complexed viral DNA requires L1-specific antibody. Sarcoid extract (C7) was left undiluted (100) or
serially 10-fold diluted (10−1–10−4) in extraction buffer as indicated. Following incubation with monoclonal antibodies 1H8 or 5B6 directed against BPV-1 L1, or
murine IgG as control, L1-specific PCR was carried out. The reaction scored positive for all extract dilutions when using L1-specific capture antibody (lanes 1–5 and
8–12), but only for undiluted extract, when coating unspecifically (lane 15). 0: extraction buffer (no template control); p+: positive control (BPV1-pML plasmid, PCR
step only); M: GeneRuler™ 100 bp DNA Ladder Plus (Fermentas).
Table 2
Presence of L1 protein-complexed BPV DNA in sarcoid-affected horses per
sample type analysed
Tissue type collected Number of samples IC/PCR positive
Verrucous sarcoid 5 1
Nodular sarcoid 2 2
Fibroblastic sarcoid 7 7
Mixed sarcoid 7 3
Perilesional skin 2 2
Intact skin 2 1
Serum 1 0
Σ 26 16 (61.5%)
436 S. Brandt et al. / Virology 375 (2008) 433–441sarcoid (A1), 1 mixed sarcoid (H18), 1 PBMC sample (C5) and 1
dermatitis-affected skin (O30) scored negative for L1, as did all
DNAs isolated from the control group. E5 and L1 PCR results are
summarised in Table 1.
A pilot IC/PCR suggests the existence of L1 protein complexed
with BPV-1 DNA in a fibroblastic sarcoid
Single tube IC/PCR has been proven valuable for sensitive
detection of RNA and DNA viruses for which virion antibodies
are available. Virus in crude extract supernatant is captured by
virion-specific antibody coated to a reaction tube thus
concentrating the virion target. Following washing under gentle
non-denaturing conditions to avoid complex disruption, viral
DNA is released by heating and PCR amplified. In the herein
applied IC/PCR, BPV-1 L1 major capsid protein-specific
capture antibodies and PCR primers spanning a 266 bp region
of the viral L1 gene were used.
In the first attempt, IC/PCR was applied to extracts of 2
verrucous sarcoids (A1, A2) and 1 ulcerated fibroblastic sarcoid
(B3). Standard PCR from corresponding DNA isolates had
revealed E5 in 3 /3, and L1 in 2 /3 (A2 and B3) tumours (Table 1;
Fig. 1). Subsequent IC/PCR scored negative for extracts of both
verrucous lesions (A1, A2), despite the fact that PCR had
detected L1 in A2 DNA. However, IC/PCR scored positive for
the ulcerated fibroblastic sarcoid (B3) suggesting the presence of
capsid protein-associated BPV-1DNA (Fig. 1). The reactionwas
verified using BPV-1 virions (IC/PCR) and cloned BPV-1 DNA
(PCR only) as controls (Fig. 1).
BPV-1 L1 capsid protein-complexed DNA is required for IC/
PCR-mediated detection
To validate the method, we investigated whether IC/PCR can
distinguish BPV-1 capsid protein-complexed DNA from viral
episomes that may be released during mechanical tissue
disruption, adhere non-specifically to antibody and/or tube
walls and resist to washing. To this aim, BPV-free tissue extracts
prepared from a mast cell tumour (S35) were spiked with L1
gene-containing DNA isolated from intact skin (C6) or a
fibroblastic sarcoid (C7). Spiked extracts as well as sarcoid
extract (C7) were subjected to IC/PCR. The reaction scored
positive for the sarcoid, whereas no amplicons were obtained for
the mastocytoma spiked with L1 gene-positive DNAs (Fig. 2)ruling out detection of viral DNA adhering non-specifically to the
reaction tube.
To further study specificity of antigen trapping, serial ten-
fold dilutions of sarcoid extract (C7) were analysed in reaction
tubes that had been alternatively coated with two different
capsid protein-specific antibodies, 1H8 and 5B6, or murine IgG
as a control. Undiluted or serially 10-fold diluted (100 to 10−4)
sarcoid extracts scored positive by IC/PCR using L1-specific
antibodies, whereas only undiluted extract scored positive in
murine IgG-coated tubes (Fig. 3). Taken together these results
indicated that detection by IC/PCR requires the presence of viral
genome in a complex with BPV-1 L1 capsid protein.
IC/PCR detects L1 capsid protein-associated BPV-1 DNA in
58.3% of sarcoids, perilesional skin or intact skin of
sarcoid-bearing horses
We next examined 21 sarcoids classified as verrucous (n=5),
nodular (n=2), fibroblastic (n=7) or mixed types (n=7) by IC/
PCR. Two perilesional and 2 intact skin biopsies from sarcoid-
bearing horses were also analysed, as were dermatitis-affected
skin and intact skin from an otherwise healthy individual. IC/
PCR scored positive for all tested nodular (2 /2) and fibroblastic
(7 /7) sarcoids, 3 /7 mixed, and 1 /5 verrucous sarcoids, and also
for 1 /2 perilesional skin specimen (N29) (Table 2). In contrast,
capsid protein-associated BPV-1 DNAwas only detected in 1 /5
(N27) verrucous lesions. For 7 mixed sarcoids collected from 3
horses only 3 tested positive, all derived from one individual
with ulcerated tumours of the prepuce (D8–D10). Serum (D11)
of this latter patient was negative by IC/PCR. Mixed sarcoids
Fig. 4. IC/PCR reveals capsid protein-complexed BPV-1 DNA in 14 /24 samples derived from sarcoid-bearing horses. Tissue extract supernatants (and 1 serum; D11)
derived from 10 sarcoid-affected individuals (D–N), and three healthy equines (P–R) as controls were analysed by IC/PCR. L1-specific 266 bp amplimers obtained for
14 out of 24 samples derived from the patient group indicate presence of L1-containing DNA in a complex with immunopurified major capsid protein in these
specimens. Healthy equine controls scored negative, as expected. m: mixed, f: fibroblastic, v: verrucous, n: nodular sarcoid; se: serum; sk: intact skin; p: perilesional
skin; d: dermatitis; v+: BPV-1 virion positive control; a.d.: sterile water (no template control); M: GeneRuler™ 100 bp DNA Ladder Plus (Fermentas).
437S. Brandt et al. / Virology 375 (2008) 433–441from two other horses (H18, J19–J21) scored negative, whereas
perilesional skin (J22) tested positive. Interestingly, L1-
complexed DNA was also detected in distant intact skin (K24)
of a horse with an ulcerated fibroblastic sarcoid of the nostrils,
whereas intact skin (G17) was negative from a horse with
fibroblastic and nodular sarcoids of the ears. Both affected (O30)
and normal skin (O31) from an individual with advanced
granulomatous dermatitis of the hind legs (E5-positive by
standard PCR) tested IC/PCR negative, which had been
expected on the basis of negative L1-standard PCR. As
expected, tissue extracts from the control group (P–T) also
scored negative by the reaction. IC/PCR using BPV-1 virions or
water served as the appropriate controls. Results are shown in
Fig. 4 and summarised in Table 1.Fig. 5. IC/PCR detects capsid protein-complexed full-length BPV-1 DNA in extract
nodular sarcoid (N28), or from skin of healthy equines (Q33, R34) as controls were le
performed with BPV-1-specific back-to-back primers and highly processive polymera
and 1:10 diluted sarcoid extracts (lanes 2–5), whereas healthy equine controls scoreQuantitative IC/PCR reveals low concentrations of capsid
protein–DNA complexes in the majority of tissue specimens
We further determined the amount of capsid protein-
associated BPV DNA in equine sarcoids using quantitative IC/
PCR (IC/qPCR). IC/PCR-positive tissue extracts and control
specimens were subjected to IC, washed, and trapped complexes
were analysed by qPCR using serially diluted plasmid BPV1-
pML as standard. IC/qPCR revealed protein–DNA complexes at
concentrations of b125 DNA molecules per 50 µl tissue extract
for the majority of tested specimens (D8–D10, F14, G15, G16,
J22, K24, M26 and N27). 254 complexes (±30 standard
deviation [SD]) were detected per 50 µl perilesional skin extract
N29. A higher number of DNA molecules per 50 µl extract wass of two sarcoids. Extract supernatants prepared from a fibroblastic (F13) and a
ft undiluted (100) or diluted 1:10 (10−1) in extraction buffer. Subsequent IC/PCR
se resulted in amplification of the entire BPV-1 genome (7945 bp) from undiluted
d negative, as anticipated. M: GeneRuler™ 1 kb DNA ladder (Fermentas).
438 S. Brandt et al. / Virology 375 (2008) 433–441detected in a nodular sarcoid (N28; 52,800±2970 SD), or a
fibroblastic sarcoid (F13; 118,500±10,610 SD). Large amounts
of capsid protein-complexed BPV-1 DNA in these two sarcoid
specimens were associated with severity of disease. Individual N
suffered frommultiple sarcoids— a rapidly progressingmass on
its prepuce and verrucous tumours of the neck. Individual F was
affected by hundreds of verrucous, nodular and fibroblastic
sarcoids on the thorax, and a large ulcerated fibroblastic tumour
on the stifle (F13) for which the highest amount of complexed
DNAwas determined. As expected, intact skin specimens (P32,
Q33, R34) and no template controls (extraction buffer, TE
buffer) scored negative in the assay. For fibroblastic tumour K23
complex amounts could not be determined, which may be due to
repeated freezing and thawing, negatively affecting the quality
of this sample. IC/qPCR results are listed in Table 1.
Sarcoids contain full-length viral genome complexed to L1
Finally we determined whether full-length BPV genomes are
present in the L1-DNA complex in sarcoids. Immunocapture
with antibody 5B6 was performed on undiluted and 1/10 diluted
extracts of two sarcoids (F13, N28), or skin of two healthy
individuals (Q33, R34) as controls. The amplification reaction
was carried out with BPV-1-specific back-to-back primers and
highly processive DNA polymerase allowing reliable detection
of the entire BPV-1 genome. As shown in Fig. 5, amplimers of
about 8 kb were detected for undiluted and 1 /10 diluted sarcoid
extracts, whereas skin extracts derived from healthy individuals
scored negative. These results strongly support the presence of
full-length viral genomes in a complex with L1 in these two
sarcoid specimens.
Discussion
It is widely accepted that infection with BPV-1, or less
frequently BPV-2, is causally involved in the pathogenesis of
equine sarcoids, which represent the most common skin tumour
in horses. However, biology and epidemiology of BPV infection
in the foreign equine host are in large part unknown. Intradermal
injection of horses with cell-free supernatant from minced
bovine papillomas has led to the development of fibroblastic
tumours. Unlike naturally occurring sarcoids, experimentally
induced lesions regressed spontaneously, indicating that addi-
tional factors may contribute to disease progression. As an
exceptional case, a single induced lesion has persisted and cell-
free inoculum of this tumour has produced a similar lesion in
another animal (Olson and Cook, 1951). In addition, BPV-1 L1
transcripts have been detected in 50% (10 /20) of sarcoids,
indicating the possibility that BPV-1 infection may at least
occasionally be productive in horses (Nasir and Reid, 1999).
Arguing to the contrary, studies of sarcoids using electron
microscopy or antibody-based techniques have failed to
demonstrate BPV virions (Amtmann et al., 1980; Lancaster,
1981). In cattle and other species, the papillomavirus life cycle is
strictly linked to the state of epithelial cell differentiation.
Whereas early gene expression and DNA replication occur in
undifferentiated basal and suprabasal cell layers, expression oflate genes is restricted to terminally differentiated cells, where
new virions are formed and released. In horses, BPV infects
fibroblasts that may not provide the cellular environment
required for the final steps of virion production.
Assuming that virions are required to infect horses, BPV
may spread from infected cattle, e.g. by insect vectors such as
face flies (Kemp-Symonds, 2000), or via contaminated habitual
surroundings such as tack, barns or stable walls (Bogaert et al.,
2005; Chambers et al., 2003a) as virus resists desiccation for
days without loosing infectivity (Roden et al., 1997). However,
if sarcoids are productive lesions horses may spread BPV
infection also directly to their stable mates. This possibility is
supported by the occasionally successful experimental passage
of the virus in horses, and the occurrence of sarcoids in clusters
(Ragland et al., 1966). Moreover, in a study of more than 4000
donkeys, sarcoid disease has mostly affected animals kept in
close contact (Reid et al., 1994).
Prior to IC/PCR, DNA specimens were examined for viral
genes E5 and L1 by standard PCR, demonstrating BPV infection
in 100% of our patients. Sequencing of E5 amplified from two
sarcoids revealed BPV-1 E5 variant Swiss III which has been
proposed to be associated with equine sarcoids. In comparison to
bovine isolates, this E5 variant contains nucleotide substitutions
G3921T and A3938G, the latter of which may promote an
increase in codon usage (up to 5-fold) and thus more efficient
translation of the E5 oncogene in equine cells (Chambers et al.,
2003b; Nasir and Reid, 2006). In contrast to previous reports
(Angelos et al., 1991; Nasir et al., 1997) BPV E5 DNAwas also
detectable in PBMC from sarcoid-affected individual C. This
finding has been corroborated in an additional cohort of sarcoid-
bearing horses (Brandt et al., in press). However, attempts to
demonstrate L1-DNA in blood cells of sarcoid-bearing equines
and to detect L1 protein-associated BPV DNAvia IC/PCR have
failed (not shown). Thus it appears unlikely that infectious
virions are produced by PBMCs of BPV-infected equines.
Following experiments conducted by standard E5 and L1
PCR, a highly sensitive IC/PCR method (Brandt et al., 1993,
1995) was applied in a pilot experiment and scored positive in
case of 1 /3 tested sarcoid extracts. To confirm authenticity of
this preliminary result indicating the presence of capsid protein-
complexed BPV-1 DNA in a sarcoid, we evaluated the pos-
sibility that IC/PCR detects free viral DNA adhering to coated
tube walls, rather than L1-complexed DNA.However, virus-free
extract spiked with up to 4.6 µg of BPV-positive DNA
(containing 4×107 copies of E5 gene by real-time PCR) scored
negative by IC/PCR. Furthermore, when sarcoid extracts were
diluted over a wide range and reacted either with L1-specific
antibody or unspecific control-IgG, IC/PCR scored positive for
all dilutions using antibody directed against L1, whereas IC/
PCR amplification product resulting from unspecific binding to
isotype was only obtained for undiluted sarcoid extract.
Given that IC/PCR proved specific, the method was used to
screen a series of different sarcoid types and skin biopsies. IC/
PCR scored positive for 14 sample specimens derived from
horses with verrucous, nodular, fibroblastic or mixed sarcoids
out of 24 tested. Since low target concentrations were assumed,
5B6-mediated immunopurification was combined with 47
439S. Brandt et al. / Virology 375 (2008) 433–441amplification cycles as to enhance sensitivity of the test.
Subsequently, quantitative IC/PCR from positive extracts
demonstrated that the majority of tissues contained only limited
amounts of capsid protein-complexed viral DNA. This finding
could explain previous failure to detect them by less sensitive
methods. High levels of DNA-L1 complexes were detected in a
fibroblastic sarcoid (F13) from a horse bearing multiple
progressive, therapy-resistant tumours for many years, indicat-
ing a possible association with severity of disease.
Finally, we have demonstrated the presence of full-length
BPV1 circular genome in a complex with L1 in 2 /2 tested
sarcoids. This finding supports the possibility that whole virions
might occasionally be produced in equine sarcoids. However,
capture antibody 5B6 reacts with both, intact BPV-1 capsid and
L1 pentamer subunits, thus IC/PCR cannot distinguish between
pre-viral structures, e.g. DNA associated with L1-pentamers
(capsomers) at an early stage of virus assembly, or fully assembled
virions. Additional studies are warranted to elucidate the nature of
these complexes and their contribution to equine sarcoid biology.
Materials and methods
Sample collection and processing
The here described study was conducted in a cohort of 19
horses divided into a patient group and a control group. The
patient group comprised 13 horses with clinically diagnosed
sarcoids (individuals A–N) and one individual with granuloma-
tous dermatitis (individual O). The control group consisted of 5
sarcoid-free individuals that were clinically unremarkable (P, Q,
R) or affected by non-sarcoid tumours (S, T). Tumour material
was collected from each sarcoid-bearing horse of the patient
group. From some affected individuals, we equally took biopsies
from distant intact skin (C6, G17, K24) and perilesional skin
(J22, N29). In one case, serum (D11) was isolated. In another,
PBMCs were purified from whole blood (16 ml) via Ficoll
gradient centrifugation (C5). In addition, affected (O30) and
intact skin (O31) were collected from a horse with granuloma-
tous dermatitis. Supposedly BPV-free tissuematerial comprising
intact skin specimens (P32, Q33, R34), a mastocytoma (S35), a
grey horse melanoma (T36) and cartilage (T37) of the
melanoma-affected horse were collected from individuals of
the control group. Sample specifications are itemised in Table 1.
Tissue specimens (except B4 andC6 that were too small) were
grossly bisected into∼3 mm3 fractions as to allow simultaneous
DNA isolation for PCR and extract preparation for IC/PCR.
DNA purification was carried out from all tissue samples and
from PBMCs using DNeasy™ Tissue extraction kit (Qiagen). β-
actin PCR was routinely performed from thus obtained DNA
isolates as to confirm their successful purification.
Extracts were prepared from tissue fractions (except B4, C6)
by mincing them mechanically in 2 ml reaction tubes each
containing 1 ml 0.5 M Tris–HCl pH 8.2, 2% (w/v) PVP K25,
1% (w/v) PEG 6000, 0.14 M NaCl and 0.05% Tween 20.
Following centrifugation for 5 min at 13,000 rpm and 4 °C, thus
obtained tissue supernatants were kept on ice for immediate use
or stored at −20 °C.To generate an IC/PCR virus control, cow warts (kindly
provided by Richard Roden, Johns Hopkins University,
Baltimore, MD) were minced with a scalpel, re-suspended in
PBS and frozen in liquid nitrogen. Subsequently, tissue was
disrupted mechanically for 3 min using a Mixer Mills MM 200
(Retsch, Haan, Germany) and centrifuged at 10,000 g, 4 °C, for
5 min. Thus obtained supernatant containing BPV-1 virion was
stored at −70 °C before use.
BPV-1/2 E5 and L1 standard PCR
Prior to immunocapture-sustained PCR analyses, tissue derived
DNA isolates and PBMC DNA in one case were screened for
presence of viral genes E5 and L1 by standard PCR. DNA samples
K23, K24 and O31 were subjected to E5 PCR only. BPV-1/-2
consensus primers 5′E5 (5′-CACTACCTCCTGGAATGAA-
CATTTCC-3′)/3′E5 (5′-CTACCTTWGGTATCACATCT-
GGTGG-3′) were used for amplification of a 499 bp region
spanning the entire E5 oncogene. BPV-1/-2 consensus primers 5′
L1 (5′-GCTAAGCAACAACAGATTCTGTTGC-3′)/3′ L1 (5′-
TCAGCCATTTTGAGGTAGTCTGG-3′) were designed for
amplification of a 266 bp sequence of the L1 capsid gene.
Both primer pairs were selected according to published BPV-1
and BPV-2 sequences X02346 and M20219, respectively. PCR
was carried out in a final volume of 50 µl, containing 10 mM
Tris–HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 9.5% DMSO,
1.5 mM of each dNTP, 100 pmol of sense and antisense primer,
2 µl of DNA template and two drops of mineral oil as top layer.
After a hot start at 95 °C for 5 min and addition of 1 U of Taq
polymerase (Roche Diagnostics GmbH, Vienna, Austria), a
reaction program consisting of seven touch-down cycles
{denaturation at 92 °C for 30 s; primer annealing at 65 °C–
56 °C (L1) or 67 °C–58 °C (E5) for 45 s (−1.5 °C/cycle); primer
elongation at 72 °C for 45 s} followed by 40 standard cycles
{92 °C for 30 s; 56 °C (L1) or 58 °C (E5) for 45 s; 72 °C for 45 s}
and a final elongation step {72 °C for 5 min} was conducted in
an Eppendorf Mastercycler (Eppendorf-Netheler-Hinz GmbH,
Hamburg, Germany). Cloned full-length BPV-1 DNA (BPV1-
pML; p+) diluted 1:500 in sterile water and/or BPV-1-positive
sarcoid DNA (c+) were used to confirm success of PCR
reactions. 16 µl aliquots of resulting amplification products
were visualized on 1.5% Tris-acetate agarose gels by ethidium
bromide staining.
Pilot IC/PCR assay
For a pilot IC/PCR assay, four 0.65 ml MµlTI Ultra PCR
tubes (Sorenson™ BioScience, Inc., Salt Lake City, Utah, USA)
were coated with 50 µl of L1 monomer-specific mouse
monoclonal BPV-1-1H8 antibody (Abcam plc, Cambridge,
UK) diluted 1:50 in 0.1 M sodium carbonate buffer pH 9.6 and
incubated at 4 °C overnight. Subsequently, tubes were washed
twice with PBS-Tween (phosphate buffered saline pH 7.2, 0.1%
Tween 20) and rinsed thrice with PBS. Then, 50 µl aliquots of
tissue extract supernatants A1 (L1-negative control), A2, B3
and purified BPV-1 virion diluted 1:100 in extraction buffer as
IC/PCR-positive control (v+) were applied to pre-coated tubes
440 S. Brandt et al. / Virology 375 (2008) 433–441and incubated at 4 °C overnight. After washing thoroughly as
described above, L1 PCR was carried out in a total volume of
50 µl/tube under defined conditions, including cloned full-
length BPV-1 DNA (p+) as additional positive control for PCR
only. 16 µl aliquots of resulting amplification products were
visualized on 1.5% Tris-acetate agarose gels by ethidium
bromide staining.
Specificity of IC/PCR
To investigate whether IC/PCR products might have resulted
from unspecific attachment of free viral DNA to antibodies or
tube walls, IC/PCR was simultaneously performed from sarcoid
extract supernatant (C7) and from 50 µl aliquots of virus-free
skin extract supernatant (S35) spiked with L1-positive (4.6 µg
DNA of skin sample C6; 2.6 µg DNA of sarcoid C7) or L1-
negative DNA (10 µl DNA of PBMC isolate C5) obtained from
sarcoid-bearing individual C. L1 monomer-specific murine
monoclonal anti-BPV-1-1H8 (Abcam) served as capture anti-
body in this experiment.
To assess specificity of antibody trapping, reaction tubes
were alternatively coated with antibody 1H8 (Abcam), L1
capsomere-specific murine monoclonal antibody 5B6 or
isotype-matched murine IgG (donation from Armin Saalmüller,
Veterinary University Vienna, Austria). Subsequent IC/PCRwas
carried out from tumour extract supernatant C7 serially diluted
from 100 to 10−4 in extraction buffer, the latter equally serving as
negative control. Purified BPV-1 virion 1:100 was used to
confirm successful IC/PCR-mediated virus detection.
Screening of tissue specimens by IC/PCR
Extract supernatant from 17 tumour specimens comprising 3
verrucous (E12, L25, N27), 2 nodular (G16, N28), 5 fibroblastic
(F13, F14, G15, K23, M26) and 7 mixed sarcoids (D8, D9,
D10, H18, J19, J20, J21), a serum sample (D11), extract
supernatant from 3 intact skin biopsies (G17, K24, O31), 2
perilesional skin samples (J22, N29), 1 dermatitis specimen
(O30) and 3 skin biopsies obtained from clinically unremark-
able horses (P32, Q33, R34) as negative controls were subjected
to IC/PCR using antibody 5B6 for antigen trapping. Purified
BPV-1 virion diluted 1:100 in extraction buffer served as
positive control. Sterile water was used as no template control in
this experiment.
Quantification of capsid protein-complexed BPV-1 DNA
Extract supernatants from IC/PCR-positive fibroblastic (F14,
F14, G15, K23, M26), nodular (G16, N28), verrucous (N27)
and mixed sarcoids (D8–D10), perilesional skin (J22, N29) and
intact skin (K24), as well as three IC/PCR-negative extract
samples (P32, Q33, R34) from the control group were subjected
to immunocapture, using L1 capsomer-specific antibody 5B6 as
described. Extraction buffer was included in this step as no
template control. Following washing and addition of 50 µl
buffer TE (10 mM Tris–HCl, pH 8.0, 1 mM EDTA)/tube,
samples were incubated at 95 °C for 10 min. Subsequently, 5 µlaliquots of thus heat-released DNA were subjected to 25 µl-
qPCR performed in duplicate each containing 80 mM Tris–
HCl, 20 mM (NH4)2SO4, 0.02% w/v Tween 20, 3.5 mMMgCl2,
0.2 mM dNTPs, 200 nM primer (5′EG-L1 and 3′EG-L1),
0.4×EvaGreen™ dsDNA-binding dye (Biotium, Hayward,
CA, USA), 1 U of a Taq DNA polymerase chemically modified
for “hot start” (HotFIREPol®, Solis Biodyne) and 5 µl sample
or standard DNA. qPCR consisting of an initial hot start at
95 °C for 15 min followed by 50 amplification cycles (95 °C for
15 s, 59 °C for 30 s, 72 °C for 30 s) was conducted in the
LightCycler 480® System (Roche Applied Science). A
subsequent amplicon melting analysis confirmed the absence
of primer dimerisation and the BPV-1 L1 amplicon-specific
melting temperature, as determined by MeltCalc© (Schütz and
von Ahsen, 1999). The non-linearised plasmid pML-BPV-1 was
10-fold serially diluted in TE (108 to 103 copies). To improve
the accuracy of quantification in samples with low copy
numbers, two-fold serially diluted standards (200, 100, 50, 25
and 12.5 copies) were included. The amount of capsid protein-
complexed BPV-1 DNA per 50 µl tissue extract supernatant was
calculated based on standard curve analysis and the quantitative
detection limit of 12.5 copies of the L1 qPCR assay. Primers 5′
EG-L1 (5′-GCCCGTCCATGTGTTACTGAT-3′) and 3′EG-L1
(5′-TTTTGAATGTCAAGAGGTAGATCTGATT-3′) designed
with the Primer Express software 1.5 (Applied Biosystems,
Foster City, CA, USA) for amplification of a 164 bp BPV-1 L1
fragment were selected according to the BPV-1 reference
sequence X02346. Copy numbers per 5 µl qPCR template were
determined by the LightCycler 480® software release 1.3.0.075
using the Absolute Quantification/2nd Derivative Maximum
modus. Finally, copy numbers were given per 50 µl tissue extract.
IC/PCR-mediated detection of capsid protein-associated
full-length BPV-1 DNA
Undiluted and 1 /10 diluted extract supernatants of two
sarcoid specimens (F13, N28) and two healthy skin samples
(Q33, R34) were incubated in 0.5 ml reaction tubes pre-coated
with antibody 5B6 as described. Following washing, PCR was
carried out in a total volume of 50 µl, each containing 5 µl of
10× Expand Long Template buffer 1 (Roche), 9.5% DMSO,
1.5 mM of each dNTP, 100 pmol of primers 5′BPV1-6046 and
3′BPV1-6045 and two drops of mineral oil as top layer. After a
hot start at 95 °C for 5 min and addition of 4 U of Extend Long
Template Enzyme mix (Roche), a reaction program consisting
of seven touch-down cycles {denaturation at 92 °C for 30 s;
primer annealing at 65 °C–56 °C for 45 s (−1.5 °C/cycle);
primer elongation at 68 °C for 8 min} followed by 40 standard
cycles {92 °C for 30 s; 56 °C for 45 s; 68 °C for 8 min} and a
final elongation step {68 °C for 10 min} was conducted in an
Eppendorf Mastercycler (Eppendorf-Netheler-Hinz GmbH,
Hamburg, Germany). Back-to-back primers 5′BPV1-6046 (5′-
GCTAAGCAACAACAGATTCTGTTGC-3′) and 3′BPV1-
6045 (5′-ATCTAGGCCTGTTTGTTTCCTGTCATC-3′) were
selected from sequence X02346 and designed for amplification
of a 7945 bp sequence corresponding to the entire BPV-1
genome. 16 µl aliquots of resulting amplification products were
441S. Brandt et al. / Virology 375 (2008) 433–441visualized on a 1% Tris-acetate agarose gel by ethidium bro-
mide staining.
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